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NifedipineAbstract Calcium-channel blockers have an important role in the treatment of several cardiovas-
cular disorders. Derivatives of 1,4-dihydropyridines are one of the most potent calcium antagonists.
In this study a series of novel 1,4-dihydropyridine calcium channel blockers of general formula
diethyl 4-(4-substituted phenyl)-1,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxylate were synthe-
sized and tested for hypotensive activity, including electrocardiographic and effect on heart rate.
Compound diethyl 4-(4-benzyloxy phenyl)-1,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxylate
(DHP I) and diethyl 4-(2-(2-chlorobenzyloxy) phenyl)-1,4-dihydro-2,6-dimethylpyridine-3,
5-dicarboxylate (DHP III), were the most potent in this series. All synthesized compounds lowered
rat blood pressure signiﬁcantly in comparison with DMSO as control and nifedipine was used as
positive control.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
One of the most important goals in organic and medicinal
chemistry is the design and synthesis of molecules that have va-
lue as therapeutic agents. In this regard, heterocyclic com-pounds have proven to be versatile support structures that
offer a high degree of structural diversity (Weiner, 1988).
1,4 Dihydropyridines exhibit various activities such as the
calcium channel antagonists (Triggle, 2007) and the heterocyclic
ring is the common feature for various pharmacological activi-
ties such as antihypertensive, antianginal (Love et al., 1974;
Bossert et al., 1981; Breitenbucher and Figliozz, 2000), antitu-
mor (Boer and Gekeler, 1995), anti-inﬂammatory (Briukhanov,
1994; Bahekar et al., 2002), antitubercular (Wachter and Davis,
1998), analgesic (Gullapalli and Ramarao, 2002), and anti-
thrombotic (Sunkel et al., 1990; Onohandkinura, 1981). It binds
to L-type channel and also shows action by binding to N-type
channel (Triggle, 1999). Other activities are found to be reported
such as vasodilation (Wilson and Giswold, 2003), anticonvul-
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Figure 1 Scheme I for synthesis of DHP.
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et al., 2002), cardio depressant activity (Budriesi et al., 2008),
antibacterial (Chhillar et al., 2006), antileishmanial agents
(Pandey et al., 2010), cystic ﬁbrosis transmembrane conduc-
tance regulator activity (Cateni et al., 2009), mineralocorticoid
receptor antagonist activity (Arhancet et al., 2010), neuropro-
tection properties (Leon et al., 2008), HIV-1 protease inhibitors
(Hilgeroth andLilie, 2003), Alzheimer’s disease (Contelles et al.,
2009), antifertility agent (Waghmare et al., 2011).
Calcium-channel blockers have an important role in the
treatment of several cardiovascular disorders (Mirkhani
et al., 1999; Parmley et al., 1996). They have been widely used
for hypertension, angina pectoris, heart failure and Raynaud’s
disease (Safak and Simsek, 2006; Epstein et al., 2007).
Structurally diverse group of compounds are known to be
effective as calcium channel antagonists (Goldmann and
Stoltefuss, 1991). The most potent class of antagonists com-
prises derivatives of 1,4-dihydropyridine of which nifedipine
is used widely today (Haria and Wagstaff, 1995; Hadizadeh
et al., 2007). Dihydropyridines act by inhibiting the inﬂux of
calcium ion into the vascular smooth muscle cells via L-type
calcium channels (Meredith and Elliott, 2004). Their useful
effects in management of cardiovascular disorders are due to
their ability to relax vascular smooth muscles.
In angina pectoris, such drugs decrease the resistance in sys-
temic and coronary arterial beds, thereby reducing cardiac
oxygen requirement and increasing cardiac oxygen supply,
respectively.
In this paper, we describe the design and synthesis of
4-substituted 1,4-dihydropyridine derivatives and its hypoten-
sive effect on measuring rat blood pressure using invasive
in vivo technique on canulation with right carotid artery system.
1.1. Drug design
Work done in our laboratory on QSAR studies on dihydropyri-
dines by selecting a series reported by Chang et al., (Chang
et al., 2010), was used for carrying out the present study on
antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarbox-
ylates towards voltage-dependent L-type Ca2+ channels
CaV1.3 and CaV1.2. Work done in our laboratory on QSAR
studies on DHP, shows the developed MLR (Abraham et al.,
2003), model reveals that the descriptor T_T_N_2 negatively
contributes to the biological activity. T_T_N_2 is an Alignment
Independent (AI) descriptor that signiﬁes the count of the num-
ber of any atoms (single double or triple bonded) separated
from the nitrogen atom (single, double or triple bonded) by a
distance of two bonds in a molecule. The next descriptor
SsssCHcount is inversely proportional to the activity. This
descriptor deﬁnes the total number of –CH group connected
with three single bonds. The descriptor, SdCH2count is also
negatively contributing to the biological activity. It is the total
number of –CH2 group with double bond. The descriptor
T_T_O_6 is positively contributing to the activity. It is the
count of the number of any atoms (single, double or triple
bonded) separated from any other oxygen atom (single, double
or triple bonded) by a distance of six bonds in a molecule. The
last descriptor, rotatable bond count is negatively contributing
to the activity. On the basis of these QSAR inferences the li-
gands were designed that accomplish the requirements. Among
the several designed analogues only top four molecules that
were predicted to be active were selected for synthesis.2. Materials and methods
Melting points were determined by open capillary tubes using
VEEGO VMP-D digital melting point apparatus and are
uncorrected. FTIR spectra of the powdered compounds were
recorded using KBr on a JASCO FTIR 4100 series and are re-
ported in cm1 and 1H NMR spectra were recorded on a Var-
ian Mercury YH300 (300 MHz FT NMR) spectrophotometer
using TMS as an internal reference (Chemical shift represented
in dppm). Purity of the compounds was checked on TLC
plates using silica gel G as stationary phase and iodine vapours
as visualizing agent.
2.1. General procedure for the preparation of compounds ALD
I–ALD III
As shown in Scheme I (Lin et al., 2005; Chang et al., 2001)
(Fig. 1), the starting substituted phenol (0.1 mol) was dissolved
in THF (100 ml). To the solution was added substituted benzyl
chlorides (0.13 mol), K2CO3 (20 g), and KI (26 g). The result-
ing mixture was stirred under reﬂux for 6 h. The solvent was
removed in vacuum. Water (100 ml) was added and the mix-
ture was extracted with CHCl3, dried over MgSO4, and evap-
orated. The residue was puriﬁed by recrystallization to yield
respective derivatives.
2.2. Procedure for the synthesis of 4-oxo-4H-chromene-3-
carbaldehyde (ALD IV)
As shown in Scheme II (Lacova et al., 1998) (Fig. 2), dry
dimethylformamide (121 ml) in a three-necked ﬂask, POCl3
(0.49 mol) was added slowly with intensive stirring at 50 C.
Heating and stirring were continued for 2 h at 45–55 C. The
solution of 2-hydroxyacetophenone (0.12 mol) in DMF
(25 ml) was then slowly added under stirring at 50 C. The stir-
ring was continued for 2 h at 55–60 C. After cooling the mix-
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512 P.A. Datar, P.B. Autiture was kept overnight at room temperature and diluted slowly
by adding crushed ice (500 g) and stirred again for 6 h. The
crystals were ﬁltered off and recrystallized from alcohol.
2.3. General procedure for the preparation of compounds DHP
I–IV
As shown in Scheme III (Hantzsch, 1881) (Fig. 3), A mixture
of the aldehyde (3.3 mmol), ethylacetoacetate (6.6 mmol),
NH4OAc (4.95 mmol) was dissolved in 10 ml of ethanol at
80 C for an appropriate time (generally 1–10 h). After com-
pletion of the reaction, as indicated by TLC (n-hexane: ethyl
acetate, 4:1), it was poured into ice cold water and extracted
with ethyl acetate. The organic layer was washed with sodium
thiosulphate, with water, dried, and concentrated in vacuum.
The crude products were puriﬁed by recrystallization to yield
the ﬁnal product.3. Pharmacology
3.1. Animals
Wistar rats weighing in the range 250–300 g were obtained
from National centre for cell science (NCCS), Pune, India.
Six rats were used for each dose of compound. The control
group received DMSO (1 ml/kg i.p.) only. All the test com-
pounds were dissolved in DMSO. Animals were housed in
standard cages, under standard ambient conditions, tempera-
ture (25 ± 2 C), and relative humidity of 50%± 5%. A
12:12 h light: dark cycle was maintained. All the animals were
allowed to have free access to water and standard palletized
laboratory. All the experimental procedures and protocols
used in these studies were reviewed and approved by the Insti-
tutional Animal Ethics Committee (IAEC) of College, Pune,
constituted in accordance with the guidelines of the Committee
for the Purpose of Control and Supervision of Experiments on
Animals (CPCSEA), Government of India.
3.2. Preparation of dose for test compounds
All compounds were prepared by dissolving in DMSO, test
samples were administered to test animals intraperitoneally.Dose calculation details were as per literature (Jorjani et al.,
2003; Liang et al., 2002; Zhou et al., 2011).
3.3. In vivo pharmacological screening
(i) Inﬂuence on blood pressure: Inﬂuence on blood pressure
was analysed in adult normotensive Wistar rats (250–
300 g) under urethane anaesthesia (1.26 gm/kg i.p.).
The right carotid artery was exposed and cannulated
with a polyethylene tube ﬁlled with small volumes of
heparin solution (20 IU/ml, in physiological saline) for
the measurement of the mean arterial pressure of the
rats. The heparin solution was injected in the arterial
catheter at 30 min intervals, to avoid possible blood
coagulation. The catheter (PE-50) was connected to
the blood pressure transducer and the transducer was
connected with the eight-channel data acquisition sys-
tem (Power lab 8/35). Data processing and analysing
was carried out by ChartTM 5 version 5.5.6 software
(AD Instruments, Australia). All test compounds DHP
I–IV and standard (nifedipine 10 mg/kg) were dissolved
in DMSO (Nekooeian et al., 2009; Pathan et al., 2007)
and administered intraperitoneally (10 mg/kg i.p.).
Thereafter, mean values in blood pressure measurement,
measured before and after drug administration of 0, 15,
30, 45 and 60 min time interval were determined (Zhou
et al., 2011; Mohajeri et al., 2011; Balaev et al., 2010;
Hadizadeh et al., 2005, 2007).
(ii) Inﬂuence on normal electrocardiogram: Recording of
the electrocardiogram is an essential tool in the evalua-
tion of antiarrhythmic drugs. Similar to the heart rate,
the electrocardiogram is different between various spe-
cies. Electrocardiographic investigations were carried
out with the application of subcutaneous needle elec-
trodes to the ﬂexor aspect of limbs of rat and connected
with the SS2L electrode transducer which was connected
with the eight channel data acquisition system (Power
lab ADInstruments, Australia) with the respective
ECG transducer and blood pressure. Physiological
ECG recordings were taken from Wistar rats (250–
300 g) anaesthetized with urethane (1.26 gm/kg i.p.)
and, afterwards, compounds under investigation were
injected. Test compounds were administered intraperito-
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collected at 0, 15, 30, 45 and 60 min of administration of
compounds.
(iii) Inﬂuence on the heart rate: Heart rate recordings were
taken from Wistar rats (250–300 g) with the application
of subcutaneous needle electrodes to the ﬂexor aspect of
limbs of rat and connected with the SS2L electrode
transducer, which was connected with the eight-channel
data acquisition system (Power lab) with the respective
ECG transducer and blood pressure. Rats were anaes-
thetized with urethane (1.26 gm/kg i.p.) and, afterwards,
test compounds were injected. Test compounds were
administered intraperitoneally with the dose of 10 mg/
kg. Heart rate (in beats per min) was recorded at 0,
15, 30, 45 and 60 min of administration of compounds.4. Result and discussion
4.1. Chemistry
All compounds were yellow to orange crystalline powders.
They were stable when exposed to daylight and to artiﬁcial
light. The synthetic route used to synthesize title compounds
is outlined in Scheme III (Hantzsch, 1881), (Fig. 3). The
starting material, was prepared according to the method
reported in the literature. In this synthesis aromatic substituted
aldehydes were synthesized and were used for dihydropyridine
synthesis.
4.1.1. 4-(Benzloxy)benzaldehyde (ALD I)
Yield: 86.45% (solid), mp 66–67 C, FTIR (KBr) cm1: 3071.0
(Ar C–H); 1696.09 (C‚O); 1505.17 (Ar C–C); 1058.73 (CH3–
O–).
4.1.2. 4-(2,4-Dichlorobenzloxy)benzaldehyde (ALDII)
Yield: 45.65% (solid); mp 107–109 C. FTIR (KBr) cm1:
3076.87 (C–H); 1686.44 (C‚O); 1581.34 (C–C); 1037.52
(CH3–O–).
4.1.3. 4-(2-Chlorobenzloxy)benzaldehyde (ALD III)
Yield: 49.50% (solid); mp 168–170 C, FTIR (KBr) cm1:
3074.94 (C–H); 1688.44 (C‚O); 1563.99 (C–C); 1038.48
(CH3–O–).
4.1.4. 4-Oxo-4H-chromene-3-carbaldehyde (ALD IV)
Yield: 77.51% (solid), mp 137–139 C, FTIR (KBr) cm1:
3054.69 (C-H); 1697.05 (C‚O); 1452.14 (C–C), 1305.57 (cyclic
ether), 1641.14 (cyclic ketone).
As shown in Scheme I (Fig. 1), the starting substituted phe-
nols (I) were subjected to o-benzylation by reacting with
substituted benzyl chloride in THF, in the presence of
K2CO3, to yield the corresponding substituted benzyloxyben-
zaldehydes derivatives (ALD I–III) (Lin et al., 2005; Chang
et al., 2001). Scheme II (Lacova et al., 1998) (Fig. 2) shows,
a Vilsmeier–Haack reaction of 2-hydroxyacetophenone with
POCl3 and DMF to give oxochrome derivatives. Scheme III
(Hantzsch, 1881) (Fig. 3) shows, a well known Hantzsch dihy-
dropyridine synthesis to obtain ﬁnal derivative. The structures
of various synthesized compounds were assigned on the basis
of different chromatographic, spectral studies and qualitative
and quantitative organic analytical studies. The physical data,FTIR, and 1H NMR spectral data for all the synthesized com-
pounds are reported in experimental protocols.
4.1.5. Diethyl 4-(4-(benzyloxy) phenyl)-1, 4-dihydro-2,6-
dimethylpyridine-3,5-dicarboxylate (DHP I)
Yield: 29.74% (solid); mp 157–159 C. FTIR (KBr) cm1:
3351 (N–H); 1695.12 (C‚O–O); 1482.99 (CH2,CH3); 3035.41
(Ar C–H); 1644.98 (Ar C–C). 1H NMR (DMSO, d ppm):
8.726 (1H, s, –NH–); 7.483–6.802 (9H, m, aromatic H); 5.146
(2H, s, –OCH2–); 5.049 (1H, s, –CH–); 2.477–2.225 (4H, m,
2–OCH2–); 2.144 (6H, m, 2 –CH3); 1.333 (3H, t, –CH3);
1.287 (3H, t, –CH3).
4.1.6. Diethyl 4-(2-(2,4-dichlorobenzyloxy)phenyl)-1,4-
dihydro-2,6-dimethylpyridine-3,5-dicarboxylate (DHP II)
Yield: 31.26% (solid); mp 150–152 C. FTIR (KBr) cm1:
3347.82 (N–H); 1492.63 (CH2,CH3); 1725.98 (C‚O–O);
3222.54 (Ar C–H); 1566.92 (Ar C–C); 476.331 (C–Cl). 1H
NMR (CDCl3, d ppm): 7606–6.759 (7H, m, aromatic H),
5.388 (2H, s, –CH2–), 5.080 (1H, s, –CH–), 2.606 (2H, s,
–OCH2–), 2.396 (2H, s, –OCH2–), 2.176 (6H, m, 2–CH3),
1.416 (3H, t, –CH3), 1.284 (3H, t, –CH3).
4.1.7. Diethyl 4-(2-(2-chlorobenzyloxy) phenyl)-1,4-dihydro-
2,6-dimethylpyridine-3,5-dicarboxylate (DHP III)
Yield: 26.00% (solid); mp 265–267 C. FTIR (KBr) cm1:
3428.81 (N–H); 1403.92 (CH2, CH3); 1720.19 (C‚O–O);
3261.04 (Ar C–H); 1530.56 (Ar C–C); 466.689 (C–Cl). 1H
NMR (CDCl3, d ppm): 7.281–6.220 (8H, m, aromatic H);
4.295 (2H, s, –CH2-); 4.272 (1H, s, –CH–); 2.433–2.315 (4H,
m, 2–OCH2–); 2.279 (6H, m, 2CH3); 1.311 (3H, t, –CH3);
1.287 (3H, t, –CH3).
4.1.8. Diethyl 1,4-dihydro-2,6-dimethyl-4-(4-oxochroman-3-
yl)pyridine-3,5-dicarboxylate (DHP IV)
Yield: 29.42% (solid); mp 237–239 C. FTIR (KBr) cm1:
3322.75 (N–H); 1444.00 (CH2, CH3); 1718.26 (C‚O–O);
3104.83 Ar C–H); 1226.5 (cyclic ether); 1633.41 (cyclic ketone).
1H NMR (CDCl3, d ppm): 8.155–7.273 (4H, m, aromatic H);
4.170–4.133 (2H, dd, –CH2–); 4.108 (1H, s, –CH–); 4.071–
4.060 (1H, t, –CH–); 2.956 (4H, m, –OCH2–); 2.301 (6H, m,
2 –CH3); 1.276 (3H, t, –CH3); 1.252 (3H, t, –CH3).
4.2. Pharmacology
In the present study, the following pharmacological tests were
carried out to assess the effect on normal electrocardiogram
(ECG), hypotensive and effect on the heart rate of synthesized
compounds. All compounds were administered at a dose of
10 mg/kg i.p. per compound. Power lab instrument was used
for data acquisition. Body temperature was recorded using a
rectal thermostat probe and was maintained at 37 ± 0.5 C
using an incandescent lamp placed over the abdomen. After
stabilization, arterial blood pressure (systolic, diastolic and
mean), and heart rate were recorded.
The title compounds (DHP I and DHP III) (10 mg/kg, i.p.)
produced blood pressure lowering effect (Table 1, Fig. 4) and
the heart rate is constant in urethane-anesthetized normoten-
sive Wistar rats. (Table 2, Fig. 5). Compounds DHP II and
DHP IV did not reduce the blood pressure signiﬁcantly. Their
effects in lowering MABP were signiﬁcantly less than those of
nifedipine. There were no signiﬁcant differences between the
Figure 4 Graph – Hypotensive activity of compounds DHP I–
IV, nifedipine and control (DMSO) tested after i.p. administration
in anaesthetized normotensive rats.
Table 3 Effects of an intraperitoneal injection of the investigated
Wistar rats.
Compound code Parameter Time of observatio
0
DHP I RR 0.1663
QRS 0.0118
QT 0.0966
DHP II RR 0.1892
QRS 0.0117
QT 0.0236
DHP III RR 0.178
QRS 0.0141
QT 0.0699
DHP IV RR 0.5526
QRS 0.1911
QT 0.0964
Table 1 Responses (Mean Arterial Blood Pressure) versus time (min), following the administration of the compounds (10 mg/kg i.p.).
Compound Code Mean blood pressures [mm Hg]
0 min 15 min 30 min 45 min 60 min
DHP I 66.81 64.45 62.34 62.00 60.00
DHP II 68.99 68.00 67.25 67.00 67.00
DHP III 67.22 65.00 63.00 61.00 60.00
DHP IV 69.00 68.00 68.25 67.99 67.44
Nifedipine 66.28 64.78 63.00 62.89 60.11
Control (DMSO) 63.22 63.11 62.87 62.44 62.45
Table 2 Effects of an intraperitoneal injection of the investigated c
rats.
Compound Code Heart rate (beats per min)
0 15
DHP I 372.026 372.070
DHP II 301.072 348.020
DHP III 317.012 339.032
DHP IV 284.457 265.556
Nifedipine 392.001 392.453
Control (DMSO) 326.700 320.422
514 P.A. Datar, P.B. Autimean blood pressures before and after DMSO administration.
Nifedipine was taken as standard, at a dose of 10 mg/kg pro-
duced signiﬁcant reduction in blood pressure after dosing.
Compounds DHP I and DHP III were equipotent as compared
to nifedipine to decrease the blood pressure (Table 1, Fig. 4).
Only ortho chloro derivative and non substituted phenyl ana-
logues were effective hypotensive agents. The dichloro deriva-
tive and coumarine analogue did not show a comparable
activity. DHP I does not affect the heart rate. DHP II and
III show initial tachycardia but later show a gradual decrease
in the heart rate. DHP I–IV did not show much variation in
ECG records (Table 2 and 3; Fig. 5). Compounds DHP I
and II showed increase in the heart rate initially due to reﬂex
action, compared to DMSO. This effect could be the result
of vasodilatory effects of test compounds. The reﬂex tachycar-
dia has been previously reported (Valdivielso et al., 1997;
Nekooeian et al., 2009) for classic dihydropyridine compounds
like nifedipine.compounds (10 mg/kg i.p.) on ECG intervals in anaesthetized
n in min
15 30 45 60
0.1658 0.1610 0.1506 0.1637
0.0118 0.0116 0.0114 0.0119
0.0960 0.0931 0.0938 0.0951
0.1892 0.1892 0.1892 0.1892
0.0117 0.0117 0.0117 0.0117
0.0236 0.0236 0.0236 0.0236
0.1825 0.1839 0.1969 0.1940
0.0142 0.0146 0.0150 0.0150
0.0707 0.0719 0.0735 0.0763
0.2326 0.2327 0.2216 0.2211
0.0110 0.0110 0.0110 0.0110
0.0968 0.0951 0.0958 0.0958
ompounds (10 mg/kg i.p.) on heart rate in anaesthetized Wistar
30 45 60
370.017 367.013 363.012
320.012 326.011 332.026
330.412 325.121 307.111
256.442 269.112 278.098
307.543 297.444 311.356
320.35 322.32 320.31
Figure 5 Graph – Effects of an intraperitoneal injection of the
investigated compounds (10 mg/kg i.p.) on heart rate in anaes-
thetized Wistar rats.
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The statistical signiﬁcance of differences was estimated by
analysis of variance (ANOVA) followed by Dunnett’s test
(Dunnett, 1980). Results were expressed as the mean ± S.E.
where p< 0.05 was considered as signiﬁcant value.
5. Conclusions
Our results showed that all ﬁnal products were pure and stable
compounds. Similar to other analogues of nifedipine, they
were lipophilic compounds. DHP I to DHP IV (10 mg/kg,
i.p.) with nifedipine (10 mg/kg, i.p.) showed that all com-
pounds reduced the mean arterial blood pressure. From the de-
tailed analysis of pharmacological activities of synthesized
compounds, we concluded that the QSAR based on which
we have designed molecules, has proven to be promising at
least in these preliminary in vivo pharmacological screening
models. These compounds decreased mean arterial blood pres-
sure signiﬁcantly, while no effect on the heart rate in rats. Fur-
ther pharmacological and toxicological studies are required to
provide a comprehensive proﬁle of these compounds for their
prospective use in drug therapy.Acknowledgments
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